Estroz Tablet

Introduction

Estroz is a prescription medication that contains the active ingredient Exemestane. It is available in tablet form and is primarily used in the treatment of hormone receptor-positive breast cancer in postmenopausal women.

Uses

Estroz is prescribed to reduce the risk of breast cancer recurrence in postmenopausal women who have already received certain hormonal therapy. It is also used as an adjuvant treatment for early-stage breast cancer in postmenopausal women who have completed 2-3 years of tamoxifen therapy.

Dosage and Administration

The dosage of Estroz will be determined by your healthcare provider based on your specific condition and response to treatment. Follow the prescribed dosage instructions carefully. Typically, the recommended dose is one 25 mg tablet taken orally once daily, with or without food. Take the tablet at the same time each day to maintain consistent levels of the medication in your body.

Mechanism of Action

Exemestane, the active ingredient in Estroz, belongs to a class of medications called aromatase inhibitors. It works by reducing the production of estrogen in the body. Estrogen can promote the growth of hormone receptor-positive breast cancer cells. By inhibiting the production of estrogen, Exemestane helps to slow down or stop the growth of cancer cells.

Side Effects

Common side effects may include hot flashes, fatigue, headache, increased sweating, joint pain, and nausea. These side effects are usually mild and temporary. However, if they persist or become bothersome. Consult your healthcare provider.

In rare cases, Estroz may cause more serious side effects such as bone loss, osteoporosis, or fractures. Discuss any concerns or symptoms with your healthcare provider.

If you experience any severe or persistent side effects, such as shortness of breath, chest pain, sudden severe headache, or signs of an allergic reaction (e.g., rash, itching, swelling), seek immediate medical attention.

Drug Interactions

inform your healthcare provider about all the medications you are taking, including prescription, over-the-counter, and herbal products. Some medications may interact with Estroz and affect its effectiveness or increase the risk of side effects.

Common drug interactions may occur with medications that affect liver enzymes, such as certain antifungal medications, certain antibiotics, and certain HIV medications. Discuss potential drug interactions with your healthcare provider before starting Estroz.

Precautions

Before taking Estroz, inform your healthcare provider about any medical conditions you have, especially if you have a history of osteoporosis, liver problems, or if you are pregnant or breastfeeding.

Estroz should not be used in premenopausal women or in women who are pregnant or breastfeeding. Use effective contraception during treatment and for a period of time after discontinuing the medication.

Storage

Patient Tips

• Take Estroz exactly as prescribed by your healthcare provider. Do not take more or less than the recommended dose.
• If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule.
• Do not stop taking Estroz without consulting your healthcare provider, even if you feel well. Complete the full course of treatment as prescribed.
• If you have any questions or concerns about Estroz or its use, consult your healthcare provider for further guidance.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Aromasin (Health Professionals SmPC) Available at:
• Exemestane (Drugs.com) [Accessed 21 Jun. 2024] (online) Available at:
• exemestane 25 mg tablet aromatase inhibitors (RX) [Accessed 25 Jun. 2024] (online) Available at:
• Exemestane (MedlinePlus) [Accessed 23 Jun. 2024] (online) Available at:
• Scott LJ, Wiseman LR. Exemestane. Drugs. 1999 Oct;58(4):675-80; discussion 681-2. doi: 10.2165/00003495-199958040-00007. [Accessed 1 Jun. 2024] Available at: